World Investment Advisors Takes $456,000 Position in IDEXX Laboratories, Inc. $IDXX

World Investment Advisors acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 851 shares of the company’s stock, valued at approximately $456,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IDXX. Stratos Wealth Partners LTD. boosted its position in IDEXX Laboratories by 1.7% during the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after purchasing an additional 18 shares during the period. Red Spruce Capital LLC raised its position in shares of IDEXX Laboratories by 1.1% in the second quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock valued at $912,000 after purchasing an additional 19 shares during the period. Phoenix Financial Ltd. lifted its stake in shares of IDEXX Laboratories by 1.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 1,181 shares of the company’s stock valued at $633,000 after buying an additional 20 shares in the last quarter. Rise Advisors LLC boosted its holdings in IDEXX Laboratories by 3.9% in the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company’s stock worth $301,000 after buying an additional 21 shares during the period. Finally, Harbour Investments Inc. boosted its holdings in IDEXX Laboratories by 27.3% in the 2nd quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock worth $53,000 after buying an additional 21 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Sharon E. Underberg sold 5,450 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the sale, the executive vice president owned 6,156 shares in the company, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Nimrata Hunt sold 1,200 shares of IDEXX Laboratories stock in a transaction on Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the sale, the executive vice president directly owned 16,807 shares of the company’s stock, valued at $11,034,299.71. This represents a 6.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 54,057 shares of company stock valued at $34,293,468 over the last three months. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $722.94 on Tuesday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $735.00. The stock has a fifty day moving average of $639.53 and a 200 day moving average of $571.97. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The firm has a market capitalization of $57.84 billion, a price-to-earnings ratio of 60.19, a P/E/G ratio of 4.06 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.26. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company’s revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of analyst reports. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, August 4th. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research report on Monday. UBS Group started coverage on IDEXX Laboratories in a research note on Wednesday, October 1st. They set a “neutral” rating and a $720.00 price objective on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $688.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.